�鶹ӰԺ

Bristol Myers Squibb, a global biopharmaceutical company, recently announced the aquisition of��MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, for $13.1 billion in cash.

MyoKardia was co-founded by��Leslie Leinwand, Distinguished Professor of��Molecular, Cellular, and Developmental Biology��at CU �鶹ӰԺ's��BioFrontiers Institute,��in 2012. Learn more about Leinwand's involvement here.

Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug Application (“NDA”) for mavacamten for the treatment of symptomatic obstructive HCM – based on data from the EXPLORER-HCM study – is expected to be submitted to the U.S. Food and Drug Administration (“FDA”) in the first quarter of 2021.

Leinwand and her three co-founders shared a vision for��therapeutic innovation in treating cardiovascular disease – the number one cause of death globally. Leveraging their diverse expertise in company formation, myosin motors and heart muscle function�����Ի� genetics, the founders teamed with Third Rock Ventures to form MyoKardia, with a mission to��discover and develop novel therapeutics that could address the underlying biomechanical cause of disease for well-defined patient populations.

Leinwand (pictured right)�����Ի� her research lab��continue��to collaborate with the company, currently on finding new treatments for rare genetic diseases.